Back to School: How biopharma can reboot drug development. Access exclusive analysis here

Sutent sunitinib: Preliminary Phase II data

Preliminary data from an open-label Phase II trial in 72 patients

Read the full 115 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE